TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Utility of Postpartum Antibiotics in Chorioamnionitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of chorioamnionitis~* Undergoing cesarean section for delivery~Exclusion Criteria:~* Multiple gestations,~* Allergy to beta-lactam antibiotics~* Patients with estimated creatinine clearance (ClCr) less than 70 mL/min~* Maternal fever explained by etiology other than chorioamnionitis~* Inability to comply with the study protocol.

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Postpartum Antibiotics (Type: EXPERIMENTAL): Patients will receive one additional dose of postpartum antibiotics (Clinda, Gentamicin)
- No postpartum antibiotics (Type: PLACEBO_COMPARATOR): No further postpartum antibiotics

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin B12a Vasoplegic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any patient for whom we are able to obtain consent ahead of their procedure~* Patients presenting for a procedure in which cardiopulmonary bypass will be required~* Considered high risk for vasoplegic syndrome~* Has no contraindications to arterial line or PA catheter placement~* Develops high-dose vasopressors for 30 min or longer and refractory hypotension consistent with vasoplegic syndrome within 24 hours of coming off cardiopulmonary bypass.~Exclusion Criteria:~* Age\<18 years~* Known pregnancy or patients without a documented pregnancy test if not menopausal.~* Known prior anaphylactic or allergic reaction to B12a~* CKD stage 4 or worse~* ECMO (extracorporeal membrane oxygenation) prior to study consent.~* Patients currently on cardiopulmonary bypass

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- B12a (Type: EXPERIMENTAL): Subjects will receive Hydroxocobalamin marketed as Cyanokit®, 5g, IV
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Tolerance of Traces in Peanut/Tree Nut Allergic Children.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 2-18 years at time of inclusion~* Tree nut or peanut allergy documented by:~  * Positive skin prick tests (SPTs) to peanut and/or tree nuts~ * Positive specific IgE (sIgE) to peanut and/or tree nuts ( ≥0.35 kU/L)~ * A recent (\< 1 year) positive food challenge, reacting to the dose of 30 mg of proteins or below.~* Parent/Legal guardian has been informed about the study and has signed Informed Consent Form~Exclusion Criteria:~* History of a moderate or severe reaction during a food challenge with a dose of 30 mg of proteins or less.~* Expected non-adherence to the study protocol.~* Severe or uncontrolled asthma.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Foods with traces (Type: EXPERIMENTAL): Oral food challenge with foods with traces

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Confirmed diagnosis of T-cell large granular lymphocytic (T-LGL) leukemia~* Must have concurrent anemia or neutropenia~PATIENT CHARACTERISTICS:~* Life expectancy ≥ 2 years~* Not pregnant~* Fertile patients must use effective contraception~* No other malignancy~* No active infection~PRIOR CONCURRENT THERAPY:~* No prior immunosuppressive treatment~* No previous treatment with methotrexate or fludarabine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MTX followed by fludarabine (Type: EXPERIMENTAL): MTX is given with a dose of 10-20mg weekly Fludarabine is dosed with 25mg/m2 day 1-3 of 28 days, up to 4 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a clinical diagnosis of Type II diabetes mellitus, controlled by diet and/or second generation oral hypoglycemic drugs, with the onset of the disease after age 35.~* Are between 0 and 50% above normal body weight (adjusted by frame) according to the Metropolitan Life Insurance Tables.~* Are male or female, aged 36-80 years with a diagnosis made at least 1 year prior to enrollment.~* Have an HbA1c level between 6 and 10%~* Have a fasting serum glucose level between 120-220 mg/dL and not vary by more than ±20% during the month prior to entering the treatment phase and HbA1c levels not vary by more than ±10% during the month prior to entering the treatment phase. Serum glucose level must have been between 120-220mg/dl and the subject's HbA1c between 6 and 10% at Week 0.~* Have been on a stable diet consistent with ADA-recommended dietary guidelines with intake of total dietary fiber \< 15g/1000 calories and were willing to maintain this diet during the 20-week study.~* Have maintained a constant body weight (±5%) during the month prior to entering the treatment phase~Exclusion Criteria:~* Have a condition that would interfere with evaluation

- Gender: ALL
- Minimum Age: 36 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): matched placebo BID
- psyllium 3.4g BID (Type: ACTIVE_COMPARATOR): 3.4g psyllium BID for a Total of 6.8g daily
- 6.8g psyllium BID (Type: ACTIVE_COMPARATOR): 6.8g psyllium BID for a total of 13.6 g/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* BMI ≥ 22kg/m\^2~* Type 2 diabetes with HbA1c between 6.5% and 10.0%~* Documented symptomatic chronic heart failure (NYHA II-IV)~* Plasma NT-proBNP \> 300pg/ml~* eGFR ≥ 45ml/min/1.73m\^2 (calculated by MDRD)~Key Exclusion Criteria:~* Pregnant or nursing (lactating) women~* Type 1 diabetes, monogenic diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes~* History of ketoacidosis, lactic acidosis, or hyperosmolar coma~* Symptomatic genital infection or UTI within 4 weeks of screening~* Myocardial infarction, stroke, surgery for heart disease, percutaneous coronary intervention within 3 months of randomization~* Unstable angina within 3 months of screening~* Isolated right HF due to pulmonary disease~* Patients with a mean sitting systolic blood pressure ≤ 100mmHg, at randomization~* History of lower limb amputation~* Diabetic foot ulcer at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LIK066 2.5mg (Type: EXPERIMENTAL): Eligible participants randomized to this treatment arm received the LIK066 2.5mg dose regimen once daily for 36 weeks.
- LIK066 10mg (Type: EXPERIMENTAL): Eligible participants randomized to this treatment arm received the LIK066 10mg dose regimen once daily for 36 weeks.
- LIK066 50mg (Type: EXPERIMENTAL): Eligible participants randomized to this treatment arm received the LIK066 50mg dose regimen once daily for 36 weeks.
- Empagliflozin (Type: ACTIVE_COMPARATOR): Participants randomized to this treatment arm received empagliflozin once daily for 36 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants randomized to this treatment arm received LIK066 matching placebo and empagliflozin matching placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Procalcitonin (PCT)-Guided Antibiotic Use in Severe Sepsis Patients Without Obvious Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* hospitalized in resuscitation ward~* severe sepsis symptomatology~* at least 2 SIRS criteria~* no infectious etiology detected~* at least one organ deficiency~Exclusion Criteria:~* the presence of a pathogen agent or infectious centre clearly identified~* pregnancy~* burned~* patients with therapeutic limitation~* recent surgery~* secondary neutropenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Procalcitonin level (Type: OTHER): duration of the antibiotic treatment guided by procalcitonin level
- physician's appreciation (Type: NO_INTERVENTION): duration of the antibiotic treatment based on physician's appreciation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Protective Role of the L-DOPA Against Age Related Macular Degeneration in Parkinson's Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients aged of 70 years old and more~* Parkinson's disease~Exclusion Criteria:~* Opposition to participate in this trial~* Patient under a measure of legal protection~* Absence of affiliation to social security or universal health coverage (CMU)

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exposed patients (Type: None): Patients treated for Parkinson's disease with a cumulative dose of L-DOPA above the 59th percentile of the population
- Non exposed patients (Type: None): Patients treated for Parkinson's disease with a cumulative dose of L-DOPA below the 41th percentile of the population

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Skin biopsy in early disease showing apoptotic keratinocytes in the epidermis and in more advanced disease necrosis of the entire epidermis~* Epidermal detachment or erythematous to purpuric macules involving more than 10% of body surface area in addition to involvement of the oropharynx; there may be further involvement of other mucosal surfaces, ie. conjunctivae, gastrointestinal tract, respiratory and genitourinary epithelia~* Age of 18 years old or older~* The patient is expected to survive longer than 48 hours~Exclusion Criteria:~* Skin detachment above 90% of the body surface area~* Skin detachment has not progressed during the previous 48 hours~* A positive serum pregnancy test~* Age \< 18 years old~* Known hematologic or solid organ malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Palifermin (Type: EXPERIMENTAL): Palifermin 60 micrograms/kg/day IV for 3 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Screening Study to Identify Patients With Complement Factor I Deficiencies

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~An individual must meet all the following criteria to be eligible to participate in this study:~1. A male or female ≥6 months of age who has been diagnosed with a complement-mediated disease in which a reasonable etiological association with CFI deficiency has been reported~2. Affirmation of participant's informed consent or LAR's willingness to provide informed consent with signature confirmation before any study-related activities. (Study-related activities are any procedures that would not have been performed during normal clinical management of the participant.) The participant (if a minor) must be willing to give written informed assent if the minor is within the age groups 7 to 11 years old and 12 to 17 years old.~Exclusion Criteria:~1) Diagnosis of age-related macular degeneration that is complement-related with no concurrent systemic complement involvement

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Interest of the Peak of Reticulocytes in Chronic Hemodialysis Patients Treated by Mircera Hemodialysis Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age\> or equal to 18 years~* Patients on hemodialysis or hemodiafiltration for at least 3 months~* Patient treated monthly by Mircera® for at least one month~* Affiliate or enjoying a social security scheme~* Patients who received oral and written information about the study, with no objection to the use of personal data and having signed an informed consent form and written~Exclusion Criteria:~* Patient who refused to give his written consent to the study~* Patients treated with another Erythropoiesis stimulating agent~* Minor~* Pregnant or breastfeeding women~* Major under guardianship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reticera (Type: OTHER): A blood sample (before dialysis) under the usual conditions will be performed at D0 (= the day of Mircera® injection) and 9 days (+/- 1 day) after each injection Mircera® for hemoglobin and reticulocytes dosage for a period of 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Electrochemotherapy for Chest Wall Recurrence af Breast Cancer: Present Challenges and Future Prospects.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18~* Histological proven cancer of the breast.~* Progressive and/or metastatic disease.~* No further standard treatment for the patient available or the patient does not wish to receive the offered standard treatment.~* If Endocrine therapy: Progression in cutaneous lesions.~* If treatment with trastuzumab (Herceptin)can continue this treatment if there is no regression in cutaneous lesions.~* At least 2 weeks since last chemotherapy, patients treated with Navelbine (Vinorelbine), Capecitabin (Xeloda) or weekly Paclitaxel (Taxol)can continue this treatment if there is no regression in cutaneous metastases.~* Malignant cutaneous or subcutaneous lesion to be treated ≥ 3 cm.~* WHO performance ≤ 2.~* Life expectancy of at least 3 months.~* Platelets ≥ 50 mia/l, pp ≥ 40, APTT in normal area. Medical correction is allowed.~* Sexual active men and women must use safe anticonceptive during and up to 6 month after last treatment.~* Written informed consent must be obtained according to the local Ethics committee requirements.~Exclusion Criteria:~* Acute lung infection~* Previous bleomycin treatment exceeding 200.000 Units/m2.~* Known hypersensitivity to any of the components of the treatment.~* Known hypersensitivity to any of the components used in the planned anesthesia.~* Pregnant or lactating women. In fertile women this is ensured by measuring HCG in blood.~* Treatment with granulocyte colony stimulating factor (G-CSF) or other cytokines.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Patients with local-regional recurrence of breast cancer, lesion over 3 cm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Nitric Oxide in Prevention/Treatment of Ischemia-Reperfusion Lung Injury Related to Lung Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Patients undergoing lung transplantation~Exclusion criteria:~* Participation in other experimental protocols

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Inhaled Nitric Oxide
- 2 (Type: PLACEBO_COMPARATOR): Placebo gas

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Intravenous Lipids on Lung Function in Acute Respiratory Distress Syndrome (ARDS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed with predisposing condition causing ARDS~* are mechanically ventilated through an endotracheal tube~* have enteral feeding access~* have central venous access~* have a PaO2:FiO2 ratio of less than 200~* have bilateral pulmonary infiltrates on chest x-ray~Exclusion Criteria:~* sedation requiring the use of diprivan (after enrollment)~* a clinical diagnosis of left ventricular failure~* lung cancer~* hematologic malignancy~* severe dyslipidemia~* condition precluding bronchoscopy including inability to maintain oxygen saturations greater than 90% per pulse oximetry despite conventional mechanical ventilation~* severe immunosuppression~* use of NSAIDS within previous 24 hours~* HIV positive~* pregnancy~* hypersensitivity to egg or soybean oil~* active myocardial infarction~* acute pancreatitis if complicated by hypertriglyceridemia~* severe sepsis with 2 or more organ failures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- ClinOleic 20% (Type: EXPERIMENTAL): 96 hour continuous infusion.
- Intralipid 20% (Type: ACTIVE_COMPARATOR): 96 hour continuous infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues